Mineralys Therapeutics, Inc. (MLYS) annual cash flow statement — 6-year operating, investing & financing history
| Cash from Operations | -136.4M | -142.42M | -166.31M | -81.17M | -29.22M | -14.56M | -2.46M |
| Operating CF Margin % | - | - | - | - | - | - | - |
| Operating CF Growth % | 98.94% | 14.37% | -104.89% | -177.79% | -100.71% | -491.11% | - |
| Net Income | -151.78M | -154.65M | -177.81M | -71.9M | -29.8M | -19.41M | -3.43M |
| Depreciation & Amortization | 50K | 59K | 43K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 15.68M | 19.32M | 11.34M | 5.06M | 455K | 80K | 1K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -6.91M | -9.88M | -9.4M | -6.87M | -649K | 684K | 482K |
| Working Capital Changes | 6.56M | 2.73M | 9.52M | -7.47M | 772K | 4.08M | 480K |
| Change in Receivables | 71K | -166K | 424K | -355K | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -341.82M | -389.75M | 114.96M | -160.47M | -21.76M | 0 | 0 |
| Capital Expenditures | -15K | -15K | -96K | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 425.99M | 591M | 116.14M | 203.25M | 128.02M | 23.81M | 3.83M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 3.85M |
| Equity Issued (Net) | 419.4M | 591M | 116.06M | 202.99M | 128.02M | 23.81M | -20K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | -1.63M | 0 | 0 |
| Other Financing | 6.59M | 0 | 83K | 258K | 0 | 0 | 0 |
| Net Change in Cash | -52.23M | 58.83M | 64.79M | -38.4M | 77.04M | 9.25M | 1.41M |
| Free Cash Flow | -136.41M | -142.43M | -166.41M | -81.17M | -29.22M | -14.56M | -2.46M |
| FCF Margin % | - | - | - | - | - | - | - |
| FCF Growth % | 29.21% | 14.41% | -105.01% | -177.79% | -100.71% | -491.11% | - |
| FCF per Share | -1.65 | -2.11 | -3.43 | -2.24 | -5.65 | -2.92 | -0.53 |
| FCF Conversion (FCF/Net Income) | 0.90x | 0.92x | 0.94x | 1.13x | 0.98x | 0.75x | 0.72x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying MLYS stock.
Mineralys Therapeutics, Inc. (MLYS) generated $-142.4M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Mineralys Therapeutics, Inc. (MLYS) reported negative free cash flow of $142.4M in 2025, indicating capital requirements exceeded cash from operations.
Mineralys Therapeutics, Inc. (MLYS) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.